Tyrosine kinase inhibitor induced pancreatitis
- PMID: 23034406
- DOI: 10.1177/1078155212457968
Tyrosine kinase inhibitor induced pancreatitis
Abstract
Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Keywords: Pancreatitis; sorafenib; sunitinib; tyrosine kinase inhibitor.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical